Search
Confirm
Cancel
News

News

Fusen Pharmaceutical Stock code:1652.HK
Location:
Homepage
-
-
-
7 departments issued notices to support the development of Chinese medicine in the country. The 2 trillion market needs to be stepped up to tap the value of pharmaceuticals

7 departments issued notices to support the development of Chinese medicine in the country. The 2 trillion market needs to be stepped up to tap the value of pharmaceuticals

  • Categories:Media Information
  • Author:Lin Jing
  • Origin:Investor Network
  • Time of issue:2021-09-24
  • Views:

(Summary description)A few days ago, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and other seven departments jointly issued the "Notice on Several Measures to Support the High-Quality Development of National Traditional Chinese Medicine Service Export Bases", from improving the system and mechanism, innovating supporting policies, enhancing the level of facilitation, and expanding international cooperation. Put forward 18 specific policy measures in five aspects: space, strengthening of talent training and incentives, focus on improving the development environment, form a joint departmental policy, support the national Chinese medicine service export base to vigorously develop Chinese medicine service trade, and promote Chinese medicine service to the world. Subsequently, the National Health Commission issued the "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine." The notice emphasized that to further enhance awareness, public general hospitals should have hospital leaders who are relatively fixed in charge of traditional Chinese medicine work, and create conditions for the coordinated development of traditional Chinese and Western medicine; the health administration department should include the integration of traditional Chinese and Western medicine in the hospital review and public hospital performance evaluation , To promote the development of Chinese medicine in general hospitals. The development of Chinese medicine ushered in opportunities of the times Recently, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and other seven departments jointly issued the "Notice on Several Measures to Support the High-Quality Development of National Traditional Chinese Medicine Service Export Bases." Existing channels such as the guidance fund will increase support for the development of Chinese medicine service trade, support the base to expand international marketing channels, achieve high-quality development, and enhance the international influence of Chinese medicine. With the support of many countries' favorable policies and the fact that various localities place TCM work in a more prominent position, industry analysts believe that the inheritance and innovative development of TCM has clearly entered a new stage and embarked on a new journey. For example, from the national level to the local level, the overall plan for the development of Chinese medicine shows that the speed of innovation, research and development and industrial upgrading of Chinese medicine enterprises is accelerating, and it has begun to enter the golden period of development. The industry believes that in this context, Chinese medicine companies need to take advantage of the situation, take responsibility, inherit the essence, maintain integrity and innovation, promote the revitalization and development of Chinese medicine, and make more contributions to the health and well-being of the people and the building of a healthy China. Buchang Pharmaceuticals, as a leading Chinese medicine company, has driven the rapid development of the Chinese medicine industry and has also benefited a lot from the wave of Chinese medicine. While favorable policies for the Chinese medicine industry are frequently emerging, Buchang Pharmaceuticals seizes opportunities and adheres to the fundamentals while expanding into new areas. Not only does it grow steadily in business, it also makes contributions to the well-known pharmaceutical companies in China's Chinese medicine industry. . According to the first quarter of 2021, Buchang Pharmaceutical's research and development expenses were 78 million yuan, a year-on-year increase of 62.58%; sales expenses were 1.651 billion yuan, a year-on-year decrease of 18.78%. "One increase and one decrease" reflects the transformation process of Buchang Pharmaceutical. According to estimates by industry insiders, the development of the Chinese medicine industry will usher in good development opportunities. According to the "In-depth Research and Investment Prospect Analysis Report of the Traditional Chinese Medicine Industry Market in 2021-2025" released by the New Thinking Industry Research Center, the scale of China's traditional Chinese medicine manufacturing market has increased from 64 billion yuan to 73.5 billion yuan from 2016 to 2020. , The average annual compound growth rate reached 3.6% or more. Driven by favorable policies, the size of the Chinese medicine market is expected to reach more than 100 million yuan by 2023. Continue to improve the transformation of the big health strategy After years of development, Buchang Pharmaceuticals has formed a three-dimensional product pattern with patented Chinese patent medicines as the core, based on the cardio-cerebral vascular market, covering traditional advantages of Chinese patent medic

7 departments issued notices to support the development of Chinese medicine in the country. The 2 trillion market needs to be stepped up to tap the value of pharmaceuticals

(Summary description)A few days ago, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and other seven departments jointly issued the "Notice on Several Measures to Support the High-Quality Development of National Traditional Chinese Medicine Service Export Bases", from improving the system and mechanism, innovating supporting policies, enhancing the level of facilitation, and expanding international cooperation. Put forward 18 specific policy measures in five aspects: space, strengthening of talent training and incentives, focus on improving the development environment, form a joint departmental policy, support the national Chinese medicine service export base to vigorously develop Chinese medicine service trade, and promote Chinese medicine service to the world.

Subsequently, the National Health Commission issued the "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine." The notice emphasized that to further enhance awareness, public general hospitals should have hospital leaders who are relatively fixed in charge of traditional Chinese medicine work, and create conditions for the coordinated development of traditional Chinese and Western medicine; the health administration department should include the integration of traditional Chinese and Western medicine in the hospital review and public hospital performance evaluation , To promote the development of Chinese medicine in general hospitals.

The development of Chinese medicine ushered in opportunities of the times

Recently, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and other seven departments jointly issued the "Notice on Several Measures to Support the High-Quality Development of National Traditional Chinese Medicine Service Export Bases." Existing channels such as the guidance fund will increase support for the development of Chinese medicine service trade, support the base to expand international marketing channels, achieve high-quality development, and enhance the international influence of Chinese medicine.

With the support of many countries' favorable policies and the fact that various localities place TCM work in a more prominent position, industry analysts believe that the inheritance and innovative development of TCM has clearly entered a new stage and embarked on a new journey. For example, from the national level to the local level, the overall plan for the development of Chinese medicine shows that the speed of innovation, research and development and industrial upgrading of Chinese medicine enterprises is accelerating, and it has begun to enter the golden period of development.

The industry believes that in this context, Chinese medicine companies need to take advantage of the situation, take responsibility, inherit the essence, maintain integrity and innovation, promote the revitalization and development of Chinese medicine, and make more contributions to the health and well-being of the people and the building of a healthy China. Buchang Pharmaceuticals, as a leading Chinese medicine company, has driven the rapid development of the Chinese medicine industry and has also benefited a lot from the wave of Chinese medicine.

While favorable policies for the Chinese medicine industry are frequently emerging, Buchang Pharmaceuticals seizes opportunities and adheres to the fundamentals while expanding into new areas. Not only does it grow steadily in business, it also makes contributions to the well-known pharmaceutical companies in China's Chinese medicine industry. . According to the first quarter of 2021, Buchang Pharmaceutical's research and development expenses were 78 million yuan, a year-on-year increase of 62.58%; sales expenses were 1.651 billion yuan, a year-on-year decrease of 18.78%. "One increase and one decrease" reflects the transformation process of Buchang Pharmaceutical.

According to estimates by industry insiders, the development of the Chinese medicine industry will usher in good development opportunities. According to the "In-depth Research and Investment Prospect Analysis Report of the Traditional Chinese Medicine Industry Market in 2021-2025" released by the New Thinking Industry Research Center, the scale of China's traditional Chinese medicine manufacturing market has increased from 64 billion yuan to 73.5 billion yuan from 2016 to 2020. , The average annual compound growth rate reached 3.6% or more. Driven by favorable policies, the size of the Chinese medicine market is expected to reach more than 100 million yuan by 2023.

Continue to improve the transformation of the big health strategy

After years of development, Buchang Pharmaceuticals has formed a three-dimensional product pattern with patented Chinese patent medicines as the core, based on the cardio-cerebral vascular market, covering traditional advantages of Chinese patent medic

  • Categories:Media Information
  • Author:Lin Jing
  • Origin:Investor Network
  • Time of issue:2021-09-24 10:47
  • Views:
Information

A few days ago, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and other seven departments jointly issued the "Notice on Several Measures to Support the High-Quality Development of National Traditional Chinese Medicine Service Export Bases", from improving the system and mechanism, innovating supporting policies, enhancing the level of facilitation, and expanding international cooperation. Put forward 18 specific policy measures in five aspects: space, strengthening of talent training and incentives, focus on improving the development environment, form a joint departmental policy, support the national Chinese medicine service export base to vigorously develop Chinese medicine service trade, and promote Chinese medicine service to the world.

Subsequently, the National Health Commission issued the "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine." The notice emphasized that to further enhance awareness, public general hospitals should have hospital leaders who are relatively fixed in charge of traditional Chinese medicine work, and create conditions for the coordinated development of traditional Chinese and Western medicine; the health administration department should include the integration of traditional Chinese and Western medicine in the hospital review and public hospital performance evaluation , To promote the development of Chinese medicine in general hospitals.

The development of Chinese medicine ushered in opportunities of the times

Recently, the Ministry of Commerce, the State Administration of Traditional Chinese Medicine and other seven departments jointly issued the "Notice on Several Measures to Support the High-Quality Development of National Traditional Chinese Medicine Service Export Bases." Existing channels such as the guidance fund will increase support for the development of Chinese medicine service trade, support the base to expand international marketing channels, achieve high-quality development, and enhance the international influence of Chinese medicine.

With the support of many countries' favorable policies and the fact that various localities place TCM work in a more prominent position, industry analysts believe that the inheritance and innovative development of TCM has clearly entered a new stage and embarked on a new journey. For example, from the national level to the local level, the overall plan for the development of Chinese medicine shows that the speed of innovation, research and development and industrial upgrading of Chinese medicine enterprises is accelerating, and it has begun to enter the golden period of development.

The industry believes that in this context, Chinese medicine companies need to take advantage of the situation, take responsibility, inherit the essence, maintain integrity and innovation, promote the revitalization and development of Chinese medicine, and make more contributions to the health and well-being of the people and the building of a healthy China. Buchang Pharmaceuticals, as a leading Chinese medicine company, has driven the rapid development of the Chinese medicine industry and has also benefited a lot from the wave of Chinese medicine.

While favorable policies for the Chinese medicine industry are frequently emerging, Buchang Pharmaceuticals seizes opportunities and adheres to the fundamentals while expanding into new areas. Not only does it grow steadily in business, it also makes contributions to the well-known pharmaceutical companies in China's Chinese medicine industry. . According to the first quarter of 2021, Buchang Pharmaceutical's research and development expenses were 78 million yuan, a year-on-year increase of 62.58%; sales expenses were 1.651 billion yuan, a year-on-year decrease of 18.78%. "One increase and one decrease" reflects the transformation process of Buchang Pharmaceutical.

According to estimates by industry insiders, the development of the Chinese medicine industry will usher in good development opportunities. According to the "In-depth Research and Investment Prospect Analysis Report of the Traditional Chinese Medicine Industry Market in 2021-2025" released by the New Thinking Industry Research Center, the scale of China's traditional Chinese medicine manufacturing market has increased from 64 billion yuan to 73.5 billion yuan from 2016 to 2020. , The average annual compound growth rate reached 3.6% or more. Driven by favorable policies, the size of the Chinese medicine market is expected to reach more than 100 million yuan by 2023.

Continue to improve the transformation of the big health strategy

After years of development, Buchang Pharmaceuticals has formed a three-dimensional product pattern with patented Chinese patent medicines as the core, based on the cardio-cerebral vascular market, covering traditional advantages of Chinese patent medicines, focusing on major diseases, and cultivating large varieties. It has also become a leading domestic product. Cerebrovascular Chinese patent medicine production enterprise.

It is reported that as early as 2018, Buchang Pharmaceuticals formulated three major transformations: "transition from sales to scientific research", "transition from natural medicine (Chinese medicine) to the whole pharmaceutical industry chain", and "transition from localization to globalization". strategy. In order to effectively advance the three major transformation strategies and improve the health industry chain, Step Pharmaceutical is aggressively making progress and intensifying the integration and mergers and acquisitions of the pharmaceutical industry.

At the same time, on May 13 this year, the company's wholly-owned subsidiary Shandong Danhong, Shaanxi Buchang Pharmaceutical Co., Ltd. and Kebeiyuan (Beijing) signed the "Propranolol Hydrochloride Oral Solution (4.28mg/ml, 120ml) "Technology development contract tripartite agreement", Shandong Danhong transferred the unfulfilled contract content in the contract to Shaanxi Buchang to inherit. On June 10, the company's board of directors reviewed and approved the "Proposal on the Change of the Business Scope of Wholly Owned Subsidiaries", and the wholly-owned subsidiary Tonghua Guhong Pharmaceutical Co., Ltd. planned to change the business scope due to business development needs.

Guosheng Securities stated that since the State Council promulgated the "Outline of the Strategic Plan for the Development of Traditional Chinese Medicine (2016-2030)" and the "Chinese Medicine Law" in 2016, it has continued to support policies, from promoting the optimization of the traditional Chinese medicine industry structure, ensuring the inheritance and innovation of traditional Chinese medicine, and accelerating The three major aspects of Chinese medicine going overseas are to further develop Chinese medicine. In 2021, the State Council’s May 2021 "Several Policy Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics" proposes to encourage social capital to initiate the establishment of Chinese medicine industry investment funds, increase long-term investment in the Chinese medicine industry, and new Chinese medicine investment fields Chance.

Buchang Pharmaceuticals has benefited from this and will continue to improve its strategic transformation in the future to build a leading Chinese medicine company with core competitiveness, continue to create value, give back to shareholders with excellent performance, and at the same time vigorously promote the construction of the Chinese medicine brand and boost China Medicine goes to the world.

Fully support the adjustment of national medical policy

On the evening of July 2, Buchang Pharmaceutical announced that its holding subsidiary Jilin Tiancheng Pharmaceutical Co., Ltd. drug compound brain peptide ganglioside injection and its wholly-owned subsidiary Tonghua Guhong Pharmaceutical Co., Ltd. drug Guhong injection will be withdrawn this month Yunnan Province Medical Insurance Directory. These two drugs are the exclusive varieties of Buchang Pharmaceuticals, and the compound brain peptide ganglioside injection will achieve a sales revenue of more than 1 billion yuan in 2020.

The withdrawal from the provincial medical insurance catalogue originated from the "Drug Digestion Adjustment Plan for Drugs Exceeding the National Medical Insurance Catalogue in Yunnan Province" issued by the Yunnan Provincial Medical Security Bureau.

The compound brain peptide ganglioside injection is used to treat stroke, senile dementia, craniocerebral injury, spinal cord injury, traumatic peripheral nerve injury, and dysfunction caused by brain disease. The income in 2020 is 1.244 billion yuan.

Guhong injection is used to treat cerebrovascular diseases such as insufficient cerebral blood supply, cerebral thrombosis, cerebral embolism and cerebral hemorrhage recovery period, liver disease, neurosurgery, etc. caused by low consciousness, mental retardation, memory impairment, etc. It can also be used to treat coronary artery disease. Heart disease, vasculitis, etc.

After exiting in accordance with the national policy, due to the impact of the pharmaceutical environment, pharmaceutical companies may choose to enter the national medical insurance or purchase drugs at their own expense. (Produced by Thinking Finance)

Related News

Fusen

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.
2022-04-26
Jiaheng

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.
2022-04-19
Fusen

Fusen is "affectionate" and keeps "Shanghai" together | Fusen pharmaceutical donated more than 1.3 million yuan of Shuanghuanglian oral liquid and Qingre Jiedu oral liquid to support the front line of anti epidemic in Shanghai

Recently, the situation of COVID-19's prevention and control in Shanghai is grim, and the city's war epidemic is facing a tough test. In order to support Shanghai in overcoming the epidemic, giving love and giving back to the society, Fusen pharmaceutical, together with the Hong Kong young student power foundation, contacted the Shanghai Red Cross disaster preparedness and relief center, urgently allocated resources and donated drugs to the shelter of Shanghai Urban Footprint Museum and the shelter of Shanghai New International Expo Center. At present, all these equipment and materials have been sent out and are expected to arrive in Shanghai in the near future. Fusen pharmaceutical donation preparation (▲ Fusen pharmaceutical staff prepare anti epidemic materials) Shanghai aid materials ▲ materials from Fusen pharmaceutical to Shanghai Shuanghuanglian oral liquid ▲ materials from Fusen pharmaceutical to Shanghai Qingre Jiedu oral liquid Fusen Shuanghuanglian oral liquid is the first choice for the treatment of colds. At the same time, it has antibacterial and antiviral effects. It is also a family standing drug. It has been listed in the national catalogue of essential drugs and the national catalogue of medical insurance for many times. Over the past two years, Shuanghuanglian oral liquid has been listed as the recommended drug for prevention and treatment of pneumonia in New Coronavirus, Henan, Guangdong, Heilongjiang, Shaanxi and Beijing provinces. It has been widely used in epidemic prevention and control, and has made important contributions to fight against the epidemic situation. In April 2, 2022, covid-19, sponsored by the Chinese Academy of Chinese medicine, the Chinese Academy of Chinese medicine emergency branch, the Chinese Lung Association Branch of the Chinese Medicine Association and the Chinese Academy of Chinese medicine paediatric branch held the "new crown pneumonia epidemic prevention and control expert forum". Professor Wang Daowen of Tongji Medical College Affiliated to Huazhong University of Science and Technology pointed out that Shuanghuanglian oral liquid can improve the negative conversion efficiency of SARS-CoV-2 nucleic acid detection, and obviously promote mild. The absorption of inflammatory foci of pneumonia in patients with moderate and severe cov-19, combined with the standard treatment of covid-19, can enhance the antiviral effect, providing direct evidence-based medical evidence for the effectiveness and safety of covid-19 treatment. Fusen Qingre Jiedu oral liquid has the functions of antipyretic, bacteriostatic, anti-inflammatory, anti-virus and improving immunity. It is clinically used for fever, red face, irritability and thirst, sore throat caused by excessive heat toxin; Influenza and upper respiratory tract infection with the above symptoms. Shanghai aid team, let's go ▲ all donated materials of Fusen pharmaceutical have been fully packed. Go to Shanghai for support Share the robe with your son and keep "Shanghai" safe In the next few days, Fusen pharmaceutical will also Continue to pay attention to the situation of epidemic prevention and control in Shanghai Make every effort to provide support for the front line of anti epidemic The vicissitudes of the sea show their true colors, and see their original heart in times of crisis. Over the years, Fusen group has been keen on social public welfare undertakings, actively practicing social responsibility and returning the society with true feelings. It has successively donated more than 90 million yuan to the society, demonstrating the responsibility of the enterprise and the feelings of home and country with practical actions.
2022-04-19

WeChat

福森药业

Copyright © 2021 Fusen Pharmaceutical Company Limited

豫ICP备2021028871号  Powered by www.300.cn

Copyright © 2021 Fusen Pharmaceutical  All Rights Reserved.      豫ICP备2021028871号        Powered by www.300.cn